ArticleCell genomics2025
Germline variants and mosaic chromosomal alterations affect COVID-19 vaccine immunogenicity.
Abstract read
In one paragraph
Article in Cell genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Elucidating genetic backgrounds of myasthenia gravis in Japanese by genome-wide association studies and multi-omics analyses of thymoma.Nature communications · 2026Article
- Genetic regulation across germline and somatic variation on the Y chromosome contributes to type 2 diabetes.Nature medicine · 2026Article
- Germline polymorphisms in the immunoglobulin kappa and lambda loci underpinning antibody light chain repertoire variability.Nature communications · 2025Article
- Transcriptomic and miRNA Signatures of ChAdOx1 nCoV-19 Vaccine Response Using Machine Learning.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
64 authors.
Kyuto SoneharaDepartment of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Yoshifumi UwaminoDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan. Electronic address: uwamino@keio.jp.
Ryunosuke SaikiDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan.
Masaru TakeshitaDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.
Shinichi NambaDepartment of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Shunsuke UnoDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Tomoko NakanishiDepartment of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Japan Society for the Promotion of Science, Tokyo, Japan.
Tomoyasu NishimuraDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan; Keio University Health Center, Shinjuku-ku, Tokyo, Japan.
Tatsuhiko NaitoDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
Go SatoDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Department of Gastroenterological Surgery, Osaka University Graduate School of Medicine, Suita, Japan.
Masahiro KanaiAnalytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, USA.
Aoxing LiuAnalytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA; Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA; Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA; Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA.
Sho UchidaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Toshinobu KurafujiClinical Laboratory, Keio University Hospital, Tokyo, Japan.
Akiko TanabeClinical Laboratory, Keio University Hospital, Tokyo, Japan.
Tomoko AraiClinical Laboratory, Keio University Hospital, Tokyo, Japan.
Akemi OhnoClinical Laboratory, Keio University Hospital, Tokyo, Japan.
Ayako ShibataDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Shiho TanakaDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Masatoshi WakuiDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Shoko KashimuraDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Chiharu TomiDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Akemi HaraDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Shiori YoshikawaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Keiko GotandaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Kana MisawaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan; Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Tokyo, Japan.
Hiromu TanakaDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Shuhei AzekawaDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Qingbo S WangDepartment of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan.
Ryuya EdahiroDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan.
Yuya ShiraiDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan.
Kenichi YamamotoDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Department of Pediatrics, Osaka University Graduate School of Medicine, Suita, Japan; Division of Health Science, Osaka University Graduate School of Medicine, Suita, Japan.
Genta NagaoDepartment of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Takuo SuzukiDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.
Masato KiyoshiDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.
Akiko Ishii-WatabeDivision of Biological Chemistry and Biologicals, National Institute of Health Sciences, Kanagawa, Japan.
Shinichi HigashiueTokushukai Group, Tokyo, Japan.
Shuzo KobayashiTokushukai Group, Tokyo, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Yasushi OkazakiDiagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Naoyuki MatsumotoDiagnostics and Therapeutics of Intractable Diseases, Intractable Disease Research Center, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
Akihide MasumotoASO Iizuka Hospital, Iizuka, Fukuoka, Japan.
Hidenobu KogaASO Iizuka Hospital, Iizuka, Fukuoka, Japan.
Akinori KanaiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Japan COVID-19 Task Force
Biobank Japan Project
Yoshiya OdaDepartment of Lipidomics, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8654, Japan.
Yutaka SuzukiDepartment of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, Japan.
Koichi MatsudaLaboratory of Clinical Genome Sequencing, Department of Computational Biology and Medical Sciences, Graduate School of Frontier Sciences, The University of Tokyo, Tokyo, Japan.
Yuko KitagawaDepartment of Surgery, Keio University School of Medicine, Tokyo, Japan.
Ryuji KoikeHealth Science Research and Development Center (HeRD), Tokyo Medical and Dental University, Tokyo, Japan.
Akinori KimuraInstitute of Research, Tokyo Medical and Dental University, Tokyo, Japan.
Atsushi KumanogohDepartment of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, Suita, Japan; Department of Immunopathology, Immunology Frontier Research Center, Osaka University, Suita, Japan.
Akihiko YoshimuraDepartment of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan.
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Satoru MiyanoM&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.
Takanori KanaiDivision of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Koichi FukunagaDivision of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Naoki HasegawaDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan.
Mitsuru MurataDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan; Research Center of Clinical Medicine, International University of Health and Welfare, Tokyo, Japan.
Hiromichi MatsushitaDepartment of Laboratory Medicine, Keio University School of Medicine, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan; Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
Yukinori OkadaDepartment of Genome Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Laboratory for Systems Genetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan; Premium Research Institute for Human Metaverse Medicine (WPI-PRIMe), Osaka University, Suita, Japan. Electronic address: yuki-okada@m.u-tokyo.ac.jp.
Ho NamkoongDepartment of Infectious Diseases, Keio University School of Medicine, Tokyo, Japan. Electronic address: hounamugun@keio.jp.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccine immunogenicity is influenced by the vaccinee's genetic background. Here, we perform a genome-wide association study of vaccine-induced SARS-CoV-2-specific immunoglobulin G (IgG) antibody titers and T cell immune responses in 1,559 mRNA-1273 and 537 BNT162b2 vaccinees of Japanese ancestry. SARS-CoV-2-specific antibody titers are associated with the immunoglobulin heavy chain (IGH) and major histocompatibility complex (MHC) locus, and T cell responses are associated with MHC. The lead variants at IGH contain a population-specific missense variant (rs1043109-C; p.Leu192Val) in the immunoglobulin heavy constant gamma 1 gene (IGHG1), with a strong decreasing effect (β = -0.54). Antibody-titer-associated variants modulate circulating immune regulatory proteins (e.g., LILRB4 and FCRL6). Age-related hematopoietic expanded mosaic chromosomal alterations (mCAs) affecting MHC and IGH also impair antibody production. MHC-/IGH-affecting mCAs confer infectious and immune disease risk, including sepsis and Graves' disease. Impacts of expanded mosaic loss of chromosomes X/Y on these phenotypes were examined. Altogether, both germline and somatic mutations contribute to adaptive immunity functions.
Indexed as
Chromosome AberrationsCOVID-19COVID-19 VaccinesGerm-Line MutationImmunogenicity, VaccineAdultAgedAntibodies, ViralBNT162 VaccineFemaleGenome-Wide Association StudyHumansImmunoglobulin GImmunoglobulin Heavy ChainsMajor Histocompatibility ComplexMaleAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesImmunoglobulin GImmunoglobulin Heavy Chainsclonal hematopoiesisCOVID-19 vaccinegenome-wide association studyGraves’ diseaseimmunogenicityimmunoglobulin heavy chainmajor histocompatibility complexmosaic chromosomal alterationmosaic loss of chromosome Xmosaic loss of chromosome Ysepsis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.